Brokerages predict that Recro Pharma Inc (NASDAQ:REPH) will report $24.06 million in sales for the current fiscal quarter, according to Zacks. Four analysts have provided estimates for Recro Pharma’s earnings, with estimates ranging from $22.70 million to $26.32 million. Recro Pharma posted sales of $21.74 million during the same quarter last year, which would indicate a positive year-over-year growth rate of 10.7%. The business is expected to announce its next earnings results on Tuesday, August 6th.

On average, analysts expect that Recro Pharma will report full year sales of $91.91 million for the current year, with estimates ranging from $86.60 million to $100.95 million. For the next fiscal year, analysts anticipate that the business will report sales of $96.96 million, with estimates ranging from $87.60 million to $106.00 million. Zacks Investment Research’s sales averages are a mean average based on a survey of research firms that follow Recro Pharma.

Recro Pharma (NASDAQ:REPH) last announced its quarterly earnings results on Friday, May 10th. The specialty pharmaceutical company reported ($0.10) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.79) by $0.69. Recro Pharma had a negative net margin of 83.56% and a negative return on equity of 472.52%. The company had revenue of $25.07 million for the quarter, compared to the consensus estimate of $20.51 million.

Several analysts have issued reports on the stock. ValuEngine raised shares of Recro Pharma from a “hold” rating to a “buy” rating in a report on Wednesday, May 1st. Oppenheimer set a $18.00 price target on shares of Recro Pharma and gave the company a “buy” rating in a report on Wednesday, February 20th. Zacks Investment Research raised shares of Recro Pharma from a “hold” rating to a “buy” rating and set a $9.25 price target on the stock in a report on Wednesday, April 24th. Janney Montgomery Scott reaffirmed a “buy” rating and issued a $13.00 price target on shares of Recro Pharma in a report on Thursday, January 31st. Finally, Roth Capital reaffirmed a “neutral” rating and issued a $7.50 price target (down previously from $15.00) on shares of Recro Pharma in a report on Monday, March 25th. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of $10.95.

Shares of NASDAQ REPH traded down $0.02 on Thursday, hitting $9.29. The company’s stock had a trading volume of 144,400 shares, compared to its average volume of 357,933. Recro Pharma has a 12-month low of $4.78 and a 12-month high of $10.32. The company has a market capitalization of $202.51 million, a PE ratio of -3.73 and a beta of -0.13. The company has a debt-to-equity ratio of 4.04, a current ratio of 3.56 and a quick ratio of 3.18.

In other news, CEO Geraldine Henwood sold 144,806 shares of the business’s stock in a transaction that occurred on Monday, May 13th. The shares were sold at an average price of $8.89, for a total value of $1,287,325.34. Following the completion of the transaction, the chief executive officer now owns 342,947 shares of the company’s stock, valued at $3,048,798.83. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Arnaud Ajdler acquired 40,000 shares of the business’s stock in a transaction dated Friday, May 17th. The stock was purchased at an average cost of $9.00 per share, with a total value of $360,000.00. The disclosure for this purchase can be found here. Insiders own 20.10% of the company’s stock.

Large investors have recently bought and sold shares of the company. Renaissance Technologies LLC raised its holdings in Recro Pharma by 26.0% during the third quarter. Renaissance Technologies LLC now owns 480,500 shares of the specialty pharmaceutical company’s stock valued at $3,416,000 after acquiring an additional 99,200 shares during the period. Oppenheimer & Co. Inc. raised its holdings in Recro Pharma by 5.5% during the fourth quarter. Oppenheimer & Co. Inc. now owns 32,313 shares of the specialty pharmaceutical company’s stock valued at $229,000 after acquiring an additional 1,683 shares during the period. Rhumbline Advisers raised its holdings in Recro Pharma by 47.8% during the fourth quarter. Rhumbline Advisers now owns 23,753 shares of the specialty pharmaceutical company’s stock valued at $169,000 after acquiring an additional 7,679 shares during the period. Essex Investment Management Co. LLC raised its holdings in Recro Pharma by 1.9% during the fourth quarter. Essex Investment Management Co. LLC now owns 257,707 shares of the specialty pharmaceutical company’s stock valued at $1,830,000 after acquiring an additional 4,833 shares during the period. Finally, Monarch Partners Asset Management LLC raised its holdings in Recro Pharma by 57.4% during the fourth quarter. Monarch Partners Asset Management LLC now owns 55,857 shares of the specialty pharmaceutical company’s stock valued at $397,000 after acquiring an additional 20,367 shares during the period. 57.90% of the stock is owned by institutional investors and hedge funds.

Recro Pharma Company Profile

Recro Pharma, Inc, a specialty pharmaceutical company, develops and commercializes products for hospital and related acute care settings. The company operates in two segments, Acute Care, and Contract Development and Manufacturing. Its lead product candidate includes injectable meloxicam, which completed pivotal phase III clinical trials for the treatment of post-operative pain.

See Also: Google Finance

Get a free copy of the Zacks research report on Recro Pharma (REPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Recro Pharma (NASDAQ:REPH)

Receive News & Ratings for Recro Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recro Pharma and related companies with MarketBeat.com's FREE daily email newsletter.